The pharmaceutical industry must devote greater resources, investment and effort to address its anemic drug pipeline in the long term, rather than focusing on its bottom line in the near term.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A critical review of recent trends, and a future perspective of optical spectroscopy as PAT in biopharmaceutical downstream processing
Analytical and Bioanalytical Chemistry Open Access 07 March 2020
-
Macroscopic modeling of mammalian cell growth and metabolism
Applied Microbiology and Biotechnology Open Access 22 July 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Anonymous. Results announcement for the third quarter 2010 (GlaxoSmithKline, London) http://www.gsk.com/investors/reports/q32010/q32010.pdf (21 October 2010).
Anonymous. NICE rebuffs Tarceva. BioCentury Extra, p.3 (16 June 2010).
PricewaterhouseCoopers. Pharma 2020, Virtual R&D, Which Path Will You Take? (PricewaterhouseCoopers, New York City, 2008).
Spek, H. CLSA Healthcare Forum, New York, December 1, 2010. http://en.sanofi-aventis.com/binaries/EM_conference_Spek_Web_tcm28-29638.pdf
Shaffer, C. Nat. Biotechnol. 28, 881–882 (2010).
Ernst & Young. Beyond Borders—Global Biotechnology Report (E&Y, New York, 2009).
Anonymous. Big pharma aims for reinvention. Financial Times (12 May 2010).
Behnke, N. & Sueltenschmidt, N. Changing Pharma's Innovation DNA (Bain & Company, Boston, 2010).
Ledford, H. Nature 468, 487 (2010).
Oliver Wyman. Licensing to Win (Oliver Wyman, New York, 2008). http://www.oliverwyman.com/ow/pdf_files/OW_EN_HLS_2008_LicensingtoWin.pdf
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Kessel, M. The problems with today's pharmaceutical business—an outsider's view. Nat Biotechnol 29, 27–33 (2011). https://doi.org/10.1038/nbt.1748
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1748
This article is cited by
-
A critical review of recent trends, and a future perspective of optical spectroscopy as PAT in biopharmaceutical downstream processing
Analytical and Bioanalytical Chemistry (2020)
-
Macroscopic modeling of mammalian cell growth and metabolism
Applied Microbiology and Biotechnology (2015)
-
The Role of Brain Tumor Advocacy Groups
Current Neurology and Neuroscience Reports (2014)
-
The changing face of corporate venturing in biotechnology
Bioentrepreneur (2012)
-
The changing face of corporate venturing in biotechnology
Nature Biotechnology (2012)